Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation
Francesca Maria Quaglia(University of Verona), Antonio Cuneo(Arcispedale Sant'Anna), Gian Matteo Rigolin, Michele Laudisi(University of Ferrara), Antonio Urso(Arcispedale Sant'Anna), Eleonora Volta(Arcispedale Sant'Anna), Maria Ciccone(Arcispedale Sant'Anna), Melissa Dabusti(University of Ferrara), Massimo Negrini(University of Ferrara), Elena Saccenti(University of Ferrara)
Cited by 2
Related Papers
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells
|Experimental Hematology|2008|254
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|215
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
|Blood|2019|215
Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus
|Cancer Research|2010|213